<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101902</url>
  </required_header>
  <id_info>
    <org_study_id>CAH-300</org_study_id>
    <nct_id>NCT05101902</nct_id>
  </id_info>
  <brief_title>A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])</brief_title>
  <official_title>Pre-screening Study to Identify Adult Participants With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Who May Be Eligible for Treatment in the CAH-301 Trial With BBP-631, an Adeno-associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adrenas Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adrenas Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pre-screening study is designed to determine potential eligibility of adults with&#xD;
      classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301&#xD;
      [NCT04783181] gene therapy trial with BBP-631.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult participants diagnosed with classic CAH due to 21-OHD and who are taking&#xD;
      glucocorticoids as treatment for CAH will undergo assessments to determine their potential&#xD;
      eligibility for participation in the adult CAH-301 treatment trial with BBP-631.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Potentially Eligible for CAH-301 Study</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Overall Study</arm_group_label>
    <description>Participants will undergo antibody and genetic screen, initial pre-screening, eligibility monitoring and eligibility confirmation for potential transition to the treatment trial center once a treatment assignment in the study CAH-301 becomes available. Participation in Study CAH-300 is permitted to continue until treatment assignment is available in the treatment trial or unless, during eligibility monitoring or eligibility</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pre-Screening</intervention_name>
    <description>No intervention given</description>
    <arm_group_label>Overall Study</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants diagnosed with classic CAH due to 21-OHD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male and non-pregnant females with classic CAH (simple virilizing or&#xD;
             salt-wasting) due to 21-OHD&#xD;
&#xD;
          -  Screening/baseline 17-OHP levels &gt; 5-10 × ULN&#xD;
&#xD;
          -  Is on a daily regimen of glucocorticoid&#xD;
&#xD;
          -  Naïve to prior gene therapy or AAV-mediated therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive for anti-AAV5 antibodies&#xD;
&#xD;
          -  History of adrenalectomy and has no significant liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Kathleen M Kirby</last_name>
    <phone>+1.978.479.7640</phone>
    <email>ClinicalTrials@AdrenasTX.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mel Pozun</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Science37</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

